Samuel T. Wilkinson, MD

Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.

What is the efficacy of ECT for the treatment of dementia?

Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.